NKGen Biotech, Inc. Common Stock
NKGN
NKGN was delisted on the 4th of March, 2025.
53 hedge funds and large institutions have $143M invested in NKGen Biotech, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 3 closing their positions.
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
16% more capital invested
Capital invested by funds: $123M → $143M (+$19.2M)
10% more funds holding
Funds holding: 48 → 53 (+5)
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$8.97M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$8.78M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$5.23M |
| 4 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$1.79M |
| 5 |
GF
Gabelli Funds
Rye,
New York
|
+$1.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KC
Kepos Capital
New York
|
-$5.1M |
| 2 |
Parallax Volatility Advisers
San Francisco,
California
|
-$1.59M |
| 3 |
CL
CSS LLC
Chicago,
Illinois
|
-$1.29M |
| 4 |
FBCM
Fort Baker Capital Management
Larkspur,
California
|
-$981K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$318K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RCM
51
Robinson Capital Management
Grosse Pointe Farms,
Michigan
| $88K | +$88.2K | +9,044 | New |
|
52
UBS Group
Zurich,
Switzerland
| $17K | +$17K | +1,740 | New |
|
|
AA
53
Ancora Advisors
Cleveland,
Ohio
| $10K | – | – | – |
|
|
KC
54
Kepos Capital
New York
| – | -$5.1M | -525,000 | Closed |
|
|
55
Parallax Volatility Advisers
San Francisco,
California
| – | -$1.59M | -164,071 | Closed |
|
|
OMC
56
Old Mission Capital
Chicago,
Illinois
| – | -$112K | -11,485 | Closed |
|
NKGN Hedge Fund Activity: Q3 2022 in Review
53 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Common Stock (NKGN) for Q3 2022, worth a combined $143M — up 16% from $123M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new NKGN positions and 3 closed out — a net gain of 6 holders — while 8 added to existing stakes and 8 trimmed.
The largest buyer was Magnetar Financial, adding an estimated $8.97M. The largest seller was Kepos Capital, exiting entirely with an estimated $5.1M sold.
- 53 institutional investors held NKGen Biotech, Inc. Common Stock (NKGN) as of Q3 2022, up from 48 in Q2 2022.
- Funds reported $143M of NKGen Biotech, Inc. Common Stock stock for Q3 2022, up 16% quarter-over-quarter.
- 9 funds opened new NKGen Biotech, Inc. Common Stock positions in Q3 2022 and 3 closed out, a net change of +6 holders.
- The largest NKGen Biotech, Inc. Common Stock buyer in Q3 2022 was Magnetar Financial, an estimated $8.97M added.
- The largest NKGen Biotech, Inc. Common Stock seller in Q3 2022 was Kepos Capital, an estimated $5.1M sold.
Based on aggregated 13F filings for Q3 2022.